AA
ROIV icon

AlphaCentric Advisors’s Roivant Sciences ROIV Stock Holding History

AlphaCentric Advisors’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.71M Buy
48,355
+688
+1% +$20.3K 1.45% 5
2026
Q1 		$1.32M Buy
47,667
+2,591
+6% +$66.6K 1.32% 11
2025
Q4 		$978K Buy
+45,076
New +$889K 0.97% 19
2024
Q4 		– Sell
-100,000
Closed -$1.15M – 271
2024
Q3 		$1.15M Buy
100,000
+12,000
+14% +$137K 0.86% 39
2024
Q2 		$930K Sell
88,000
-2,000
-2% -$21.9K 0.68% 52
2024
Q1 		$949K Buy
90,000
+35,000
+64% +$377K 0.57% 65
2023
Q4 		$618K Buy
55,000
+20,000
+57% +$195K 0.41% 66
2023
Q3 		$409K Buy
+35,000
New +$396K 0.23% 98

Other funds holding ROIV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

AlphaCentric Advisors's ROIV Position: Q2 2026 in Review

AlphaCentric Advisors increased its Roivant Sciences (ROIV) stake by 1.4% in Q2 2026, buying an estimated $20.3K and bringing the position to 48,355 shares worth $1.71M. The position accounts for 1.45% of the portfolio, ranked #5.

AlphaCentric Advisors first reported a position in ROIV in Q3 2023 and has held it in 8 quarters since. 498 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

  • AlphaCentric Advisors held 48,355 shares of Roivant Sciences worth $1.71M as of Q2 2026.
  • AlphaCentric Advisors bought 688 Roivant Sciences shares in Q2 2026, an estimated $20.3K.
  • Roivant Sciences made up 1.45% of AlphaCentric Advisors's portfolio in Q2 2026, its #5 holding.
  • AlphaCentric Advisors first reported a position in Roivant Sciences in Q3 2023 and has held it in 8 quarters since.
  • 498 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on AlphaCentric Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.